Ligand Pharmaceuticals Inc. (LGDN)
XDUS 
Summary
LGDN Chart
Ligand Pharmaceuticals Q1 Earnings Call Highlights
Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
Ligand Pharmaceuticals Inc. (LGDN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ligand Pharmaceuticals Inc. ever had a stock split?
Ligand Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Todd C. Davis CEO | XDUS Exchange | US53220K5048 ISIN |
| US Country | 68 Employees | 2 Jul 2010 Last Dividend | 2 Nov 2022 Last Split | 18 Nov 1992 IPO Date |
Overview
Ligand Pharmaceuticals Incorporated is a pioneering biopharmaceutical company focused on the development and licensing of innovative biopharmaceutical assets on a global scale. With a rich history since its inception in 1987, the company has established itself as a key player in the healthcare sector. Based in Jupiter, Florida, Ligand Pharmaceuticals has forged strong alliances, licenses, and business relationships with several major industry leaders, including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. One of its notable contributions is the sale of Captisol materials, which are designed to improve the solubility and stability of drugs.
Products and Services
Kyprolis and Evomela: These are therapeutic products used in the treatment of multiple myeloma, providing vital options for patients with this challenging condition.
Rylaze: This recombinant erwinia asparaginase is designed for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in both adults and pediatric patients, marking a significant advancement in leukemia therapy.
Filspari: A dual endothelin and angiotensin II receptor antagonist, currently in development stages for rare kidney diseases and as a non-immunosuppressive treatment for immunoglobulin A nephropathy.
Teriparatide injection product: This product offers a treatment solution for osteoporosis, aiming to improve bone strength and reduce the risk of fractures.
Vaxneuvance and Pneumosil: These vaccines are intended for the prevention of invasive diseases caused by certain streptococcus pneumoniae serotypes. Vaxneuvance targets a broad range, while Pneumosil focuses on protecting children from pneumococcal pneumonia.
TZIELD: A CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 type 1 diabetes, representing a proactive approach to managing this disease.
Nexterone: A captisol-enabled formulation of amiodarone, providing a safer and more effective treatment options for those requiring this critical cardiovascular medication.
Zulresso: A captisol-enabled formulation of brexanolone for the treatment of postpartum depression, offering new hope for mothers struggling with this severe condition.
Veklury: This antiviral treatment is utilized for the management of moderate or severe COVID-19, playing a significant role in the global pandemic response.
Noxafil-IV: A captisol-enabled formulation of posaconazole for intravenous use, aimed at fighting against severe fungal infections.
Duavee: A treatment for post-menopausal symptoms in women, providing relief and comfort for those dealing with the effects of menopause.
Exemptia, Vivitra, Bryxta, and Zybev: These products span various indications, including autoimmune diseases, breast cancer, and other conditions, showcasing Ligand Pharmaceuticals' versatility in addressing a wide range of health issues.
